B Büchel
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich T, Largiader C, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 2012; 71:361-70.
Nov 9, 2012Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Nov 9, 2012Cancer Chemother Pharmacol 2012; 71:361-70
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R, Joerger M
Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities
Büchel B, Jörger M, Schürch S, Largiader C. Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities. 2012; Clinical Chemistry Annual Conference
Jan 1, 2012Assessment of metabolic 5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-related toxicities
Jan 1, 20122012; Clinical Chemistry Annual Conference
Büchel B, Jörger Markus, Schürch S, Largiader CR
Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy
Büchel B, Jörger M, Schürch S, Largiader C. Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy. Biomed Chromatogr 2012
Jan 1, 2012Characterization of endogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy
Jan 1, 2012Biomed Chromatogr 2012
Büchel B, Jörger Markus, Schürch S, Largiader CR